Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKesson
Express Scripts
Mallinckrodt
Moodys

Last Updated: April 1, 2023

Eurasian Patent Organization: These 16 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Eurasian Patent Organization

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Eurasian Patent Organization: These 16 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 10,095
Patent Title: НОВЫЕ ПЕПТИДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С РЕЦЕПТОРОМ ЭРИТРОПОЭТИНА (NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR)

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,501,801
Patent Title: НОВЫЕ ПЕПТИДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С РЕЦЕПТОРОМ ЭРИТРОПОЭТИНА

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,042
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

Drug Price Trends for JANUMET
JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,095
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV

Drug Price Trends for JANUMET
JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,042
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

Drug Price Trends for JANUMET XR
JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,095
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV

Drug Price Trends for JANUMET XR
JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

When can JANUVIA (sitagliptin phosphate) generic drug versions launch?

Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,042
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

Drug Price Trends for JANUVIA
JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

When can JANUVIA (sitagliptin phosphate) generic drug versions launch?

Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,095
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV

Drug Price Trends for JANUVIA
JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,042
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,095
Patent Title: СОЛЬ ФОСФОРНОЙ КИСЛОТЫ ИНГИБИТОРА ДИПЕПТИДИЛПЕПТИДАЗЫ-IV

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 10,370
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИН-2,4-ДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГОНАДОТРОПИН-ВЫСВОБОЖДАЮЩЕГО ГОРМОНА (PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS)

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,190
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИН-2,4-ДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГОНАДОТРОПИН-ВЫСВОБОЖДАЮЩЕГО ГОРМОНА

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

When can ORILISSA (elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 10,370
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИН-2,4-ДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГОНАДОТРОПИН-ВЫСВОБОЖДАЮЩЕГО ГОРМОНА (PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS)

Drug Price Trends for ORILISSA
ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

When can ORILISSA (elagolix sodium) generic drug versions launch?

Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,190
Patent Title: ПРОИЗВОДНЫЕ ПИРИМИДИН-2,4-ДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГОНАДОТРОПИН-ВЫСВОБОЖДАЮЩЕГО ГОРМОНА

Drug Price Trends for ORILISSA
ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,022
Patent Title: ПРОИЗВОДНЫЕ (ТИО)КАРБАМОИЛЦИКЛОГЕКСАНА В КАЧЕСТВЕ АНТАГОНИСТОВ D/DРЕЦЕПТОРА ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,364
Patent Title: ПРОИЗВОДНЫЕ (ТИО)КАРБАМОИЛЦИКЛОГЕКСАНА В КАЧЕСТВЕ АНТАГОНИСТОВ D/DРЕЦЕПТОРА

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?

Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,736
Patent Title: МЕТАНСУЛЬФОНАТ ЭТИЛОВОГО ЭФИРА 3-[(2-{[4-(ГЕКСИЛОКСИКАРБОНИЛАМИНОИМИНОМЕТИЛ)ФЕНИЛАМИНО]МЕТИЛ}-1-МЕТИЛ-1Н-БЕНЗИМИДАЗОЛ-5-КАРБОНИЛ)ПИРИДИН-2-ИЛАМИНО]ПРОПИОНОВОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА (3-[(2-{[4-HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO]-METHYL}-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDINE-2-YL-AMINO]-PROPIONIC ACID ETHYL ESTER METHANE SULPHONATE AND USE THEREOF AS A MEDICAMENT)

Drug Price Trends for PRADAXA
PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?

Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,600,381
Patent Title: МЕТАНСУЛЬФОНАТ ЭТИЛОВОГО ЭФИРА 3-[(2-{[4-(ГЕКСИЛОКСИКАРБОНИЛАМИНОИМИНОМЕТИЛ)ФЕНИЛАМИНО]МЕТИЛ}-1-МЕТИЛ-1Н-БЕНЗИМИДАЗОЛ-5-КАРБОНИЛ)ПИРИДИН-2-ИЛАМИНО]ПРОПИОНОВОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА

Drug Price Trends for PRADAXA
PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

When can VYZULTA (latanoprostene bunod) generic drug versions launch?

Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 10,595
Patent Title: ПРОИЗВОДНЫЕ ПРОСТАГЛАНДИНОВ (PROSTAGLANDIN NITROOXYDERIVATIVES)

Drug Price Trends for VYZULTA
VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

When can VYZULTA (latanoprostene bunod) generic drug versions launch?

Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,099
Patent Title: ПРОИЗВОДНЫЕ ПРОСТАГЛАНДИНОВ

Drug Price Trends for VYZULTA
VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 11,158
Patent Title: ЗАМЕЩЁННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ЛЕКАРСТВЕННЫЕ СРЕДСТВА, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF)

Drug Price Trends for SYNJARDY
SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,584
Patent Title: ЗАМЕЩЁННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ЛЕКАРСТВЕННЫЕ СРЕДСТВА, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Drug Price Trends for SYNJARDY
SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 11,158
Patent Title: ЗАМЕЩЁННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ЛЕКАРСТВЕННЫЕ СРЕДСТВА, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF)

Drug Price Trends for SYNJARDY XR
SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,584
Patent Title: ЗАМЕЩЁННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ЛЕКАРСТВЕННЫЕ СРЕДСТВА, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Drug Price Trends for SYNJARDY XR
SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 9,497
Patent Title: УСТРОЙСТВО ДЛЯ ДОЗИРОВАНИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ С ПРУЖИННЫМ БЛОКИРУЮЩИМ УСТРОЙСТВОМ, ПРИВОДИМЫМ В ДЕЙСТВИЕ ПРИ ВВЕДЕНИИ ПОСЛЕДНЕЙ ДОЗЫ (MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE)

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,801
Patent Title: УСТРОЙСТВО ДЛЯ ДОЗИРОВАНИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ С ПРУЖИННЫМ БЛОКИРУЮЩИМ УСТРОЙСТВОМ, ПРИВОДИМЫМ В ДЕЙСТВИЕ ПРИ ВВЕДЕНИИ ПОСЛЕДНЕЙ ДОЗЫ

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 10,313
Patent Title: МНОГОФАЗНЫЙ ПРЕПАРАТ ДЛЯ КОНТРАЦЕПЦИИ НА ОСНОВЕ НАТУРАЛЬНОГО ЭСТРОГЕНА (MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN)

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,844
Patent Title: МНОГОФАЗНЫЙ ПРЕПАРАТ ДЛЯ КОНТРАЦЕПЦИИ НА ОСНОВЕ НАТУРАЛЬНОГО ЭСТРОГЕНА

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 15,033
Patent Title: АНТАГОНИСТЫ МУСКАРИНОВЫХ РЕЦЕПТОРОВ АЦЕТИЛХОЛИНА (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 21,994
Patent Title: АНТАГОНИСТЫ МУСКАРИНОВЫХ РЕЦЕПТОРОВ АЦЕТИЛХОЛИНА (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,991
Patent Title: АНТАГОНИСТЫ МУСКАРИНОВЫХ РЕЦЕПТОРОВ АЦЕТИЛХОЛИНА

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 201,100,019
Patent Title: АНТАГОНИСТЫ МУСКАРИНОВЫХ РЕЦЕПТОРОВ АЦЕТИЛХОЛИНА

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 11,237
Patent Title: 4-ФЕНИЛАМИНОХИНАЗОЛИН-6-ИЛ-АМИДЫ (4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES)

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Eurasian Patent Organization Patent 200,601,849
Patent Title: 4-ФЕНИЛАМИНОХИНАЗОЛИН-6-ИЛ-АМИДЫ

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Moodys
Baxter
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.